Kiora Stock Today

KPRX
 Stock
  

USD 3.71  0.02  0.54%   

Market Performance
0 of 100
Odds Of Distress
Over 67
Kiora Pharmaceuticals is trading at 3.71 as of the 26th of November 2022; that is -0.54 percent down since the beginning of the trading day. The stock's open price was 3.73. Kiora Pharmaceuticals has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Kiora Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of June 2021 and ending today, the 26th of November 2022. Click here to learn more.
Fiscal Year End
December
IPO Date
31st of July 2015
Category
Healthcare
ISIN
US49721T3095
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. The company has 12.65 M outstanding shares of which 81.94 K shares are now shorted by private and institutional investors with about 0.17 trading days to cover. More on Kiora Pharmaceuticals

Moving against Kiora Pharmaceuticals

-0.72WMTWalmart TrendingPairCorr
-0.63MRNAModerna Potential GrowthPairCorr
-0.61XOMExxon Mobil Corp TrendingPairCorr
-0.55TWTRTwitter DelistingPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Kiora Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Kiora Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Kiora Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Kiora Pharmaceuticals generated a negative expected return over the last 90 days
Kiora Pharmaceuticals has high historical volatility and very poor performance
Kiora Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 12.06 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (5.14 M).
Kiora Pharmaceuticals currently holds about 2.43 M in cash with (10.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64.
Roughly 12.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 - Marketscreener.com
Average Analyst Recommendation
Analysts covering Kiora Pharmaceuticals report their recommendations after researching Kiora Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Kiora Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Kiora Pharmaceuticals. The Kiora consensus assessment is calculated by taking the average forecast from all of the analysts covering Kiora Pharmaceuticals.
Strong Buy1 Opinion
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Kiora Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Kiora Pharmaceuticals (KPRX) is traded on NASDAQ Exchange in USA and employs 14 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 46.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kiora Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Kiora Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Kiora Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 12.65 M outstanding shares of which 81.94 K shares are now shorted by private and institutional investors with about 0.17 trading days to cover. Kiora Pharmaceuticals currently holds about 2.43 M in cash with (10.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64.
Check Kiora Pharmaceuticals Probability Of Bankruptcy
Ownership
The market capitalization of Kiora Pharmaceuticals is $46.94 Million. Kiora Pharmaceuticals secures 12.39 % if its outstanding shares held by insiders and 12.39 % owned by institutional investors . Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Kiora Ownership Details

Kiora Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Kiora Pharmaceuticals jumping above the current price in 90 days from now is close to 99%. The Kiora Pharmaceuticals probability density function shows the probability of Kiora Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Kiora Pharmaceuticals has a beta of -3.2462. This indicates as returns on its benchmark rise, returns on holding Kiora Pharmaceuticals are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Kiora Pharmaceuticals is expected to outperform its benchmark. Additionally, the company has an alpha of 0.5464, implying that it can generate a 0.55 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 3.71HorizonTargetOdds Above 3.71
0.98%90 days
 3.71 
99.02%
Based on a normal probability distribution, the odds of Kiora Pharmaceuticals to move above the current price in 90 days from now is close to 99 (This Kiora Pharmaceuticals probability density function shows the probability of Kiora Stock to fall within a particular range of prices over 90 days) .

Kiora Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Kiora Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kiora Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kiora Pharmaceuticals' value.
InstituionSecurity TypeTotal SharesValue
Xtx Topco LtdCommon Shares13.9 K31 K
Wells Fargo CompanyCommon Shares85.00.0
View Kiora Pharmaceuticals Diagnostics

Kiora Pharmaceuticals Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Kiora Pharmaceuticals market risk premium is the additional return an investor will receive from holding Kiora Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kiora Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Kiora Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Kiora Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.

Kiora Stock Against Markets

Picking the right benchmark for Kiora Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Kiora Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Kiora Pharmaceuticals is critical whether you are bullish or bearish towards Kiora Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kiora Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Invested in Kiora Pharmaceuticals?

The danger of trading Kiora Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Kiora Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Kiora Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Kiora Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Correlation Analysis. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for analysis

When running Kiora Pharmaceuticals price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 M
Return On Assets
(0.29) 
Return On Equity
(1.24) 
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Kiora Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.